Calmodulin antagonist (inhibits calmodulin activated PDE activity with an IC50
of 68 μ
M). Inhibits growth of tamoxifen-resistant breast cancer cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21cip1.
Bosch et al.
Naphthalenesulfonamides as calmodulin antagonists.
Hidaka and Tanaka
Methods Enzymol., 1983;102:185
Tamoxifen-resistant human breast cancer cell growth: inhibition by thionidazine, pimozide and the calmodulin antagonist, W-13.
Stroble and Peterson